Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 10/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30379861 | 0.86 | ATM (0.50) | CNR2MCHR1SIGMAR1 | |
| SCHEMBL241683 | 0.85 | CA9 (0.54) | CNR2MCHR1 | |
| SCHEMBL4022611 | 0.84 | MEN1 (0.51) | CNR2MCHR1SIGMAR1 | |
| SCHEMBL18289524 | 0.81 | CA1 (0.50) | CNR2 | |
| SCHEMBL6906905 | 0.81 | CA1 (0.50) | CNR2 | |
| SCHEMBL6872283 | 0.79 | MCHR1 (0.58) | CNR2NPSR1MCHR1TAS2R14 | |
| SCHEMBL31618044 | 0.78 | HTT (0.59) | — | |
| SCHEMBL6797730 | 0.78 | CNR2 (0.50) | CNR2 | |
| SCHEMBL3884644 | 0.78 | CNR2 (0.46) | CNR2MCHR1KCNH2 | |
| SCHEMBL10983891 | 0.78 | AR (0.58) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557126-B2 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-20070254943-A1 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-11-01 | — | — | US | disclosed |
| US-7250414-B2 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-20050203167-A1 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203167-A1 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | CHRM1, CHRM2, CHRM3 | CNR2 63/4885NPSR1 197/4885MCHR1 121/4885 |
| US-20070254943-A1 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | CHRM1, CHRM2, CHRM3 | CNR2 63/4885NPSR1 197/4885MCHR1 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.